Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
Q1 2026 earnings • in 1 day
See details
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
54,06 US$
+0,28%
(+0,15) 1D
54,06 US$
-0,00% (-0,00010)
After hours
Closed: 1 may, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMRN...
Açın
53,91 US$
High
54,29 US$
Low
53,56 US$
Mkt. cap
10,45 mlrd
Avg. vol.
1,83 mln
Volume
1,34 mln
P/E ratio
29,96
52-wk high
66,28 US$
52-wk low
50,76 US$
EPS
1,80 US$
Beta
0,29
Shares outstanding
192,32 mln
No. of employees
3K
News stories
From sources across the web
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22K
Foundedmar 1997
HeadquartersSan Rafael, Kaliforniya, Amerika Birləşmiş Ştatları
Sector-
Websitebiomarin.com
Next call in 25:10:19
4 may, B.e., 16:30
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (0,91 est.)USD
Revenue / Estimate
-/ (751,68 mln est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
745,14 mln
825,41 mln
776,13 mln
874,56 mln
Cost of goods sold
310,29 mln
311,40 mln
549,56 mln
348,91 mln
Cost of revenue
310,29 mln
311,40 mln
549,56 mln
348,91 mln
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206,12 mln
232,28 mln
268,42 mln
324,16 mln
Operating expense
210,96 mln
237,12 mln
273,26 mln
329,01 mln
Total operating expenses
521,25 mln
548,52 mln
822,82 mln
677,92 mln
Operating income
223,89 mln
276,89 mln
-46,69 mln
196,64 mln
Other non operating income
-1,95 mln
4,83 mln
5,09 mln
1,02 mln
EBT including unusual items
238,09 mln
297,87 mln
-26,32 mln
-27,15 mln
EBT excluding unusual items
238,09 mln
297,87 mln
-26,32 mln
214,10 mln
Income tax expense
52,40 mln
57,34 mln
4,42 mln
19,42 mln
Effective tax rate
22,01%
19,25%
-16,79%
-71,52%
Other operating expenses
-
-
-
-
Net income
185,69 mln
240,53 mln
-30,74 mln
-46,57 mln
Net profit margin
24,92%
29,14%
-3,96%
-5,33%
Earnings per share
1,13
1,44
0,12
0,46
Interest and investment income
19,01 mln
18,83 mln
17,85 mln
19,21 mln
Interest expense
-2,86 mln
-2,68 mln
-2,58 mln
-2,78 mln
Net interest expenses
16,15 mln
16,15 mln
15,28 mln
16,43 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
245,96 mln
295,45 mln
-28,20 mln
209,68 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer